Hypothetically speaking, if leronlimab proves to work in cancer, are we expecting a licensing deal with similar terms? Or will CYDY get less of a final percentage because cancer is only in phase 2? That percentage could play a factor in determining BO vs partnering.

IMO, if an agreement for NASH is made the upfront payment is large enough, CYDY should go at cancer alone or partner with Vyera again late in the game. The more value for CYDY and shareholders the better.